¿¬±¸µ¿ÇâÁ¤º¸
Á¦¸ñ COVID-19 ȯÀÚ¸¦ Ä¡·áÇϱâÀ§ÇÑ È¸º¹±â Ç÷Àå(Convalescent plasma therapy,CPT) Ç¥ÁØ¿ë·® ±ÇÀå»çÇ×
±Û¾´ÀÌ °ü¸®ÀÚ
÷ºÎÆÄÀÏ

 


 

COVID-19 ȯÀÚ¸¦ Ä¡·áÇϱâÀ§ÇÑ È¸º¹±â Ç÷Àå(Convalescent plasma therapy,CPT) Ç¥ÁØ¿ë·® ±ÇÀå»çÇ× 



 

COVID-19 ȯÀÚ¸¦ Ä¡·áÇϱâÀ§ÇÑ È¸º¹±â Ç÷Àå»ç¿ë¿¡ ´ëÇÑ µ¥ÀÌÅÍ´Â ÇöÀç ¸Å¿ì Á¦ÇÑÀûÀÌ´Ù. ±×·¯¹Ç·Î  COVID-19 ȯÀÚ¿¡ ´ëÇÑ È¸º¹±â Ç÷Àå Ç¥ÁØ¿ë·® ±ÇÀå »çÇ×Àº ¾ÆÁ÷ ¾ø´Ù. ±×·¯³ª ¾Æ·¡ »çÇ×Àº ÇöÀç±îÁö  COVID-19 ȯÀÚ¸¦ Ä¡·áÇϱâÀ§ÇÑ È¸º¹±â Ç÷ÀåÅõ¿©¿¡ ´ëÇÑ ÀÌ¿ë °¡´ÉÇÑ Á¤º¸¸¦ ¿ä¾àÇÑ ³»¿ëÀÌ´Ù.

 

¹Ì±¹ ¿¬±¸ ÇÁ·ÎÅäÄÝ¿¡¼­ COVID-19 ¹× ±Þ¼º È£Èí±â Áõ»óÀÌ ÀÖ´Â ´ë»óÀÚ´Â 1-2 ´ÜÀ§ (´ÜÀ§´ç 300 mL, ÃÑ·® 300-600 mL)ÀÇ È¸º¹±â Ç÷ÀåÀ» ¹Þ°ÔµË´Ï´Ù.




 

±×¸² 1. Components of Whole Blood.  Source: US Clinical Trials. COVID-19 Treatment




 

 

¹Ì±¹ ±¹¸³ ȸº¹±â Ç÷Àå È®Àå ¾×¼¼½º COVID-19 ÇÁ·ÎÅäÄÝ( United States National Convalescent Plasma Expanded Access COVID-19 Protocol [NCT04338360])¿¡¼­ ±ÇÀå ¿ë·®Àº Ç÷Àå 1 ´ÜÀ§ (ÃÖ¼Ò 200mL)À¸·Î Á¦»çÇÏ¿´´Ù. (US Clinical Trials. COVID-19 Treatment. URL: https://covid.idea.medicine.uw.edu/page/treatment/drugs/human-coronavirus-immune-plasma-hcip)

 




 

±×¸² 2. - Process of Apheresis to Obtain Plasma. (Illustration: David H. Spach, MD). 

Source: US Clinical Trials. COVID-19 Treatment




 

Áß±¹¿¡¼­ ¹ßÇ¥µÈ ¿¬±¸¿¡ µû¸£¸é COVID-19 ȯÀÚ 5 ¸íÀº °¢°¢ 200mLÀÇ Ç÷ÀåÀ» 2 ȸ ¿¬¼Ó ÁÖÀÔÇÏ¿© ÃÑ 400mL¸¦ ÁÖÀÔÇßÀ½À» º¸°íÇß½À´Ï´Ù.

 

µ¿·á°ËÅä(peer reviewed)¸¦ °ÅÄ¡Áö ¾ÊÀº Áß±¹ÀÇ »çÀü Àμ⠱â»ç¿¡¼­ ÁßÁõ COVID-19 ȯÀÚ 10¸íÀº  SARS-CoV-2 ÁßÈ­ Ç×ü ¿ª°¡°¡ 1 : 640 ÀÌ»ó(SARS-CoV-2 neutralizing antibody titers above 1:640)ÀÎ Ãֱ٠ȸº¹µÈ ±âÁõÀڷκÎÅÍ ¾òÀº ȸº¹±â Ç÷ÀåÀ» 200mL ÁÖÀÔ¹Þ¾Ò½À´Ï´Ù.

 

ÁÖÀÔ ¼Óµµ(Infusion Rate): ±ÇÀå ÁÖÀÔ ¼Óµµ´Â 100-250 mL / hrÀÔ´Ï´Ù. ¾Ë·¹¸£±â ¼º ¶Ç´Â ºñ¿ëÇ÷¼º ¼öÇ÷ °ü·Ã ¹ÝÀÀÀ» ÃÖ¼ÒÈ­Çϱâ À§ÇØ ¾Æ¼¼Æ® ¾Æ¹Ì³ëÆæ(acetaminophen) ¹× µðÆæÈ÷µå¶ó¹Î(diphenhydramine)À» »çÀü Åõ¾à ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù.







 

      ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ(MedRIC) Á¦°ø





 

 

 


2020-12-30 ¿ÀÈÄ 2:20:11, Á¶È¸¼ö : 1572